Business
NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021
NRx Advancing Investigational Medicines for Critical COVID-19 and Other Respiratory Conditions, Vaccine to Prevent COVID-19 and Breakthrough Drug for Suicidal
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"NRx Advancing Investigational Medicines for Critical COVID-19 and Other Respiratory Conditions, Vaccine to Prevent COVID-19 and Breakthrough Drug for Suicidal Depression and PTSD\n\n\nRADNOR, Pa., Aug. 10, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will ring the Nasdaq Closing Bell on Tuesday, August 10, 2021 in celebration of NRx's listing on the Nasdaq Exchange. The ceremony will begin at approximately 3:45 PM ET and can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.\n\n \n \n \n \n \n \n\n \nNRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021\"As we celebrate our first grant of Emergency Use of ZYESAMI™ for COVID-19 overseas and as we initiate international trials for a novel COVID-19 vaccine, we are honored to ring the Nasdaq closing bell,\" said Prof Jonathan Javitt, MD, MPH Chairman and CEO of NRx. \"Our team has gathered from around the nation to support our credo \"Bringing Hope to Life.\" As the pandemic continues to devastate families and communities around the world, we strive to advance therapies that aim to get patients with COVID-19 back home to their families and to develop a uniquely promising vaccine that may yield improved immunity against the variants that challenge our way of life.\"\nThe US Food and Drug Administration (FDA) granted Fast Track Designation to NRx for Intravenous ZYESAMI™ (aviptadil) for the treatment of Critical COVID-19 with respiratory failure. NRx has submitted data from a Phase 2b/3 trial of intravenous ZYESAMI™ to the FDA in support of Emergency Use Authorization in the U.S. Ongoing trials, sponsored by the US National Institutes of Health aim to compare ZYESAMI to Veklury from Gilead Sciences (Nasdaq: GILD). \nNRx has also been granted exclusive worldwide development and marketing rights to the BriLife™COVIDvaccine developed by the Israel Institute for Biological Research (IIBR). Yesterday, NRx and the Government of Israel announced initiation of phase 2b/3 clinical trials in the Caucasus region in partnership with the Senator Richard Lugar Institute for Biological Research.\nIn addition to COVID and respiratory focused therapies and vaccines, NRx remains focused on its p...